Woo Hye In, Park Jisook, Lim Shinn-Won, Kim Doh Kwan, Lee Soo-Youn
Department of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Transl Med. 2021 Jan 15;19(1):34. doi: 10.1186/s12967-021-02702-y.
Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals.
A total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDD patients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine).
Among 78 MDD patients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDD patients with healthy individuals, alteration of transthyretin was observed in MDD (P = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (P = 0.007).
In proteomic analysis of plasma specimens from MDD patients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
重度抑郁症（MDD）作为常见精神障碍，缺乏客观的诊断和预后生物标志物。本研究旨在进行蛋白质组学分析，以鉴定抗抑郁治疗后表达水平发生变化的蛋白质，并研究MDD患者与健康个体之间蛋白质表达的差异。
对通过文献综述获得的总共111种蛋白质进行基于多反应监测（MRM）的蛋白质定量分析。最后，对10名健康对照者和78例MDD患者（包括基线时以及接受选择性5-羟色胺再摄取抑制剂（SSRI）或米氮平抗抑郁治疗6周后的患者）的血浆样本中的7种蛋白质进行了定量分析。
78例MDD患者中，35例接受SSRI治疗，43例接受米氮平治疗。分别有19例（54.3%）和16例（37.2%）患者对SSRI和米氮平治疗有反应。将MDD患者与健康个体进行比较，发现MDD患者中转甲状腺素蛋白发生了改变（P = 0.026）。在与SSRI治疗相关的蛋白质水平上观察到了一些差异，尽管这些差异没有统计学意义。仅在有反应的患者中，米氮平治疗前后血浆甲状腺素结合球蛋白（TBG）有所不同（P = 0.007）。
在对MDD患者血浆样本进行蛋白质组学分析时，发现MDD患者中转甲状腺素蛋白和TBG水平发生了改变，且在抗抑郁治疗后有所变化。
